KARD
Kardigan, Inc.
Related News
SEC Filings
Earnings Trend
Screening
Compare
Economic Calendar
We use cookies in accordance with European GDPR standards to improve site usability, analytics, and deliver personalized advertising.Learn moreCookie Settings
Kardigan targets genetic DCM, moderate CAVS, and post-hospitalization ASH with differentiated, biology-driven clinical programs. KARD holds $660.7M in liquid assets, providing roughly 2–3 years of run
